Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Azitra Inc (AZTR – Research Report), retaining the price target of $2.00.
Jason McCarthy has given his Buy rating due to a combination of factors that indicate potential advancement and success in Azitra Inc’s product development and strategic partnerships. The company’s financial results showed a manageable net loss with sufficient cash on hand, while the anticipation of non-dilutive capital from a partnership with Bayer could enhance their financial stability. Furthermore, the focus on ATR-12 as a lead program for treating Netherton syndrome is promising, especially with the commencement of a P1b study and expected delivery of initial data by the end of the year. The strategic move towards filing an IND for the ATR-04 program further showcases the company’s commitment to expanding its pipeline.
Moreover, the presentation of positive preclinical data at the American Society of Gene and Cell Therapy meeting underscores the therapeutic potential of ATR-12. The innovative approach of using genetically modified S. epidermidis to deliver an active fragment of LEKTI directly to the skin barrier, coupled with a safety profile bolstered by the auxotrophic design of the treatment, presents a novel and potentially effective solution for Netherton syndrome. These factors, combined with a well-designed P1b trial and preclinical data that demonstrates significant reduction in key protease activity and IL-36γ levels, contribute to the optimistic outlook on Azitra Inc’s stock, warranting McCarthy’s Buy rating.
Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AZTR in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Azitra Inc (AZTR) Company Description:
Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
